Abstract:Topic: Retinopathy of prematurity (ROP) is a severe retinal vascular disorder affecting preterm infants, potentially leading to retinal detachment and blindness. This review aims to elucidate the relationship between systemic VEGF levels and ROP. Clinical relevance: This systematic review aims to consolidate evidence from available studies to guide future research and inform clinical practice. In particular, the role of circulating VEGF-A levels in predicting ROP onset and progression, and evaluating the impact of anti-VEGF therapy on these levels, is crucial in ensuring efficacy and safety in patient care. Methods: Scopus and PubMed were searched to identify studies investigating circulating VEGF-gene products in ROP patients using immunologic assays. Two authors independently screened the literature and extracted data, employing a random-effects meta-analysis to compare VEGF levels as the ratio of means between ROP patients and controls before and after treatment, heterogeneity was reported by I2-statistics. Risks of bias and publication bias were assessed using Quality Assessment of Diagnostic Accuracy Studies-2 and funnel plots/Egger's tests, respectively. Results: Out of 941 papers, 54 were included, with 26 providing posttreatment data and 31 providing biomarker data. Findings show a significant decrease in VEGF-A levels in the first week after ROP treatment (ratio of means [95% confidence interval] 0.34 [0.25-0.45], I2 = 97%, 17 publications). Anti-VEGF therapy showed a significantly more pronounced decrease (0.31 [0.25-0.38], I2 = 40%, 7 publications) than laser treatment in the first week after treatment (0.77 [0.61-0.97], I2 = 42%, 2 publications, subgroup difference, P < 0.01), among studies with a low risk of bias. Serum samples demonstrated a more marked decrease in VEGF-A than plasma (subgroup difference P < 0.01). However, the use of blood VEGF-A concentration as a biomarker for ROP prediction has shown inconsistent trends. The risk of bias mainly stems from unclear patient selection and lack of sample timing or analytical method details. Conclusion: While anti-VEGF treatment significantly reduced blood VEGF-A levels in the first week post-ROP treatment, blood VEGF-A levels did not consistently predict ROP development. Heterogeneity in the results underscores the need for optimized analytical methods and emphasizes the importance of considering individual variation in VEGF-A concentrations independent of ROP diagnosis. Financial disclosures: The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity

Systemic Conbercept Pharmacokinetics and VEGF Pharmacodynamics Following Intravitreal Injections of Conbercept in Patients with Retinopathy of Prematurity

Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity

A Lower Dose of Intravitreal Conbercept Effectively Treats Retinopathy of Prematurity

Serum Vascular Endothelial Growth Factor Levels Before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity

SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.

Comparison of the Effectiveness of Conbercept Versus Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity

Association of serum levels of inflammatory cytokines with retinopathy of prematurity in preterm infants

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept Versus Ranibizumab for Retinopathy of Prematurity.

Comparison of the Effectiveness of Conbercept and Ranibizumab Treatment for Retinopathy of Prematurity.

Efficacy and Safety of Aflibercept and Ranibizumab in the Treatment of Retinopathy of Prematurity

Intravitreal Injection of Conbercept for Aggressive Posterior Retinopathy of Prematurity

Vascular endothelial growth factor/connective tissue growth factor and proteomic analysis of aqueous humor after intravitreal conbercept for proliferative diabetes retinopathy

Anti-vascular endothelial growth factor treatment for retinopathy of prematurity

Meta-analysis of the Efficacy and Safety of Anti-vascular Endothelial Growth Factor Inhibitor in the Treat-ment of Retinopathy of Prematurity

Vascular Endothelial Growth Factor Plasma Levels Before and after Treatment of Retinopathy of Prematurity with Ranibizumab

Evaluation of Retinal Vascularization in Retinopathy of Prematurity Regressed after Intravitreal Ranibizumab Monotherapy or Without Treatment Based on Fluorescein Angiography

Short-term Effects of Intravitreal Anti-Vascular Endothelial Growth Factor Agents on Body Weight and Multiple Systems after Treatment for Retinopathy of Prematurity

Low expression of RBP4 in the vitreous humour of patients with proliferative diabetic retinopathy who underwent Conbercept intravitreal injection

Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis

The Analysis of Foveal Microvascular Anomalies in Retinopathy of Prematurity after Anti-Vascular Endothelial Growth Factor Therapy Using Optical Coherence Tomography Angiography